EG25017A - N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials. - Google Patents

N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials.

Info

Publication number
EG25017A
EG25017A EGNA2005000202A EG25017A EG 25017 A EG25017 A EG 25017A EG NA2005000202 A EGNA2005000202 A EG NA2005000202A EG 25017 A EG25017 A EG 25017A
Authority
EG
Egypt
Prior art keywords
methyleneamino
pyridones
antimicrobials
hydroxy
alkyl
Prior art date
Application number
Other languages
English (en)
Inventor
Namal Chithranga Warshakoon
Rodney Dean Bush
Original Assignee
Warner Chilcoh Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Chilcoh Company Llc filed Critical Warner Chilcoh Company Llc
Application granted granted Critical
Publication of EG25017A publication Critical patent/EG25017A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EGNA2005000202 2002-11-09 2005-05-08 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials. EG25017A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42507002P 2002-11-09 2002-11-09
PCT/US2003/035622 WO2004043927A1 (en) 2002-11-09 2003-11-07 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials

Publications (1)

Publication Number Publication Date
EG25017A true EG25017A (en) 2011-05-25

Family

ID=32312926

Family Applications (1)

Application Number Title Priority Date Filing Date
EGNA2005000202 EG25017A (en) 2002-11-09 2005-05-08 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials.

Country Status (26)

Country Link
US (5) US6930117B2 (de)
EP (1) EP1558579B1 (de)
JP (1) JP4496083B2 (de)
KR (2) KR100896675B1 (de)
CN (1) CN1708481A (de)
AT (1) ATE372985T1 (de)
AU (1) AU2003291382B2 (de)
BR (1) BR0316107A (de)
CA (1) CA2502264C (de)
CO (1) CO5570678A2 (de)
CY (1) CY1106958T1 (de)
DE (1) DE60316338T2 (de)
DK (1) DK1558579T3 (de)
EG (1) EG25017A (de)
ES (1) ES2293036T3 (de)
HR (1) HRP20050516B1 (de)
IL (1) IL168119A (de)
MA (1) MA27643A1 (de)
MX (1) MXPA05004896A (de)
NO (1) NO330810B1 (de)
NZ (1) NZ539386A (de)
PL (1) PL377226A1 (de)
PT (1) PT1558579E (de)
RU (1) RU2311410C2 (de)
WO (1) WO2004043927A1 (de)
ZA (1) ZA200503683B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6930117B2 (en) * 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
US7973060B2 (en) * 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
EP3698794A1 (de) 2009-11-06 2020-08-26 Aerpio Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von colitis
AU2011223976B2 (en) * 2010-03-04 2015-05-21 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
ES2662332T3 (es) 2010-03-04 2018-04-06 Merck Sharp & Dohme Corp. Inhibidores de la catecol-O-metil-transferasa y su uso en el tratamiento de trastornos psicóticos
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2661435B1 (de) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
AU2014233363B2 (en) 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
JP6549140B2 (ja) 2014-02-19 2019-07-24 エアーピオ セラピューティクス インコーポレイテッド N−ベンジル−3−ヒドロキシ−4−置換ピリジン−2−(1h)−オン
EP3116503A4 (de) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta-hemmer
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
CA3026211A1 (en) 2016-06-13 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of dnmt1

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US385390A (en) 1888-07-03 Sylvantjs l
US3852900A (en) * 1973-07-18 1974-12-10 J Svec Disc type indicia recording and display device
US3853900A (en) * 1973-09-14 1974-12-10 Searle & Co 4-benzyloxy-2 (1h)-pyridones
DE2442714A1 (de) * 1974-09-06 1976-03-18 Benckiser Wassertechnik Joh A Verfahren und vorrichtung zum pumpen von fluessigkeiten mittels einer membrandosierpumpe
US5358949A (en) 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
DE4316077A1 (de) 1993-05-13 1994-11-17 Bayer Ag Substituierte Mono- und Bihydridylmethylpyridone
CA2171842A1 (en) * 1993-10-18 1995-04-27 Rahim Hani Substituted pyridine-2-ones and substituted pyridine-2-thiones as biocides
US5817825A (en) * 1994-11-02 1998-10-06 Hoechst Aktiengesellschaft Process for the preparation of 1-hydroxy-2-pyridones
US6046219A (en) 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US5849587A (en) 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
ES2330719T3 (es) 2000-12-28 2009-12-15 SHIONOGI & CO., LTD. Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2.
US6930117B2 (en) * 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones

Also Published As

Publication number Publication date
US20040097560A1 (en) 2004-05-20
CO5570678A2 (es) 2005-10-31
DK1558579T3 (da) 2008-01-14
CA2502264C (en) 2009-12-15
HRP20050516A2 (en) 2005-12-31
IL168119A (en) 2011-11-30
ES2293036T3 (es) 2008-03-16
EP1558579A1 (de) 2005-08-03
RU2005114489A (ru) 2005-11-20
AU2003291382B2 (en) 2008-07-31
JP4496083B2 (ja) 2010-07-07
US20120115876A1 (en) 2012-05-10
KR20050055792A (ko) 2005-06-13
NO20052787L (no) 2005-06-09
JP2006508133A (ja) 2006-03-09
DE60316338T2 (de) 2008-06-05
AU2003291382A1 (en) 2004-06-03
ZA200503683B (en) 2006-08-30
ATE372985T1 (de) 2007-09-15
US20070270407A1 (en) 2007-11-22
NZ539386A (en) 2008-02-29
CY1106958T1 (el) 2012-09-26
NO330810B1 (no) 2011-07-25
US20100305097A1 (en) 2010-12-02
US8133894B2 (en) 2012-03-13
US7247648B2 (en) 2007-07-24
EP1558579B1 (de) 2007-09-12
CN1708481A (zh) 2005-12-14
NO20052787D0 (no) 2005-06-09
PT1558579E (pt) 2007-11-27
RU2311410C2 (ru) 2007-11-27
HRP20050516B1 (hr) 2013-11-08
DE60316338D1 (de) 2007-10-25
CA2502264A1 (en) 2004-05-27
MXPA05004896A (es) 2005-07-22
WO2004043927A1 (en) 2004-05-27
US6930117B2 (en) 2005-08-16
US7790748B2 (en) 2010-09-07
BR0316107A (pt) 2005-09-27
US20050234045A1 (en) 2005-10-20
PL377226A1 (pl) 2006-01-23
KR20070026891A (ko) 2007-03-08
MA27643A1 (fr) 2005-12-01
KR100896675B1 (ko) 2009-05-08

Similar Documents

Publication Publication Date Title
EG25017A (en) N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials.
CY1106957T1 (el) Ν-σουλφονυλο-4-μεθυλεναμινο-3-υδροξυ-2-πυριδονες ως αντιμικροβιακοι παραγοντες
GB0125222D0 (en) Composition for the treatment of microbial infections
ECSP003699A (es) Inhibidores de fab i
IL164509A0 (en) Furyl compounds
IL164613A0 (en) Thienyl compounds
BG108498A (en) New derivatives of oxazolidinones as antibacterial agents
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
IL173377A0 (en) Compounds for the treatment of metabolic disorders
UA83266C2 (en) Oxazole derivatives of tetracyclines
GB0229081D0 (en) Multifunctional cationic photoinitiators, their preparation and use
PL371524A1 (en) Combination therapy for the treatment of bacterial infections
MXPA06000372A (es) Compuestos de silicio y su uso.
GB0103240D0 (en) Organic compounds
DK1648906T3 (da) Organo-silicium-forbindelser og deres anvendelse
MXPA04002640A (es) Esteres de analogos de 3-desoxi-vitamina d3.
MX2008001548A (es) Compuestos antitumorales.
MXPA04006600A (es) Dihidrotiazina-y dihidrotiopiran-oxazolidinonas antimicrobianas.
IL164536A0 (en) The use of hydroxypyridone-derivatives in wound healing
DE60220504D1 (en) Tryptasehemmer
GB0205327D0 (en) compounds
GB0620005D0 (en) Compounds